1. Meningococcal vaccine. From capsular polysaccharides of microbes to proteases
- Author
-
A P Alliluyev, I V Anokhina, L D Rumsh, E E Melnikov, O V Kotelnikova, E A Sitnikova, E J Drozzina, L S Zhigis, E J Yagudayeva, O A Razgulyaeva, V S Zueva, L V Kozlov, and A E Avakov
- Subjects
вакцины ,полисахарид ,менингит ,IgA1 протеаза ,Medicine - Abstract
Microbial capsular polysaccharides for many years provided a highly practical public health vaccines for preventing meningococcal, pneumococcal and Haemophilus influenza infection, and typhoid fever. Their application in the form of conjugates with protein carriers eliminate the gap in protection against these infections in children under one year. Extremely promising turned out offered us a new generation of vaccines, which have synthetic peptides conjugated to a meningococcal polysaccharide. Thus, new approaches to the solution of the problem of meningococcal disease vaccination serogroup B were open. In recent years, Russian researchers first suggested to use IgA1 protease (one of the major virulence factors of microbes and almost identical for mentioned below infections) for prevention of such diseases as meningococcal of all serogroups, pneumococcus and hemophilia infections. Patented processes for producing of the vaccine define domestic priority of its production and use.
- Published
- 2012